Trials / Completed
CompletedNCT01653262
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- UCB Pharma SA · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in subjects with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side effects; as well as the efficacy, safety and tolerability of BRV. No statistical hypothesis testing will be performed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brivaracetam |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2012-07-30
- Last updated
- 2018-07-11
- Results posted
- 2016-08-15
Locations
12 sites across 5 countries: United States, France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01653262. Inclusion in this directory is not an endorsement.